Shares of Myriad Genetics (NASDAQ:MYGN) opened at 29.46 on Wednesday. The firm has a market capitalization of $2.07 billion and a PE ratio of 19.91. Myriad Genetics has a one year low of $28.82 and a one year high of $46.24.
Advertisement
For the fourth quarter, Myriad reported earnings of 36 cents a share on revenue of $186.5 million, while analysts had forecast 37 cents a share on revenue of $187.7 million. The company reported $0.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.38 by $0.06. During the same period in the prior year, the firm earned $0.41 EPS. -EPS Decline (Y-o-Y): -12.2% -Analysts Estimate: $0.38 -Revenue (Q4): $186.5 Mln vs. $189.9 Mln past year. Analysts are modeling earnings $1.89 per share on revenue of $848.29 million.
A number of other analysts have also issued reports on the company.
Myriad Genetics, Inc. (NASDAQ:MYGN) reached at $29.99 price level during last trade its distance from 20 days simple moving average is -5.11%, and its distance from 50 days simple moving average is -5.48% while it has a distance of -19.67% from the 200 days simple moving average.
Barclays downgraded MYGN stock from Overweight to Equal Weight and slashed the target price from $50 to $24. Zacks Investment Research lowered Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 1st.
Myriad Genetics, Inc. has 70,298,000 shares which are now outstanding with a price of 29.46 calculating Myriad Genetics, Inc.’s market capitalisation to 2.07B Dollars. The stock has an average rating of “Hold” and an average target price of $39.23. The company has a consensus rating of “Hold” and a consensus price target of $38.31.
Previously for the quarter ended on 12/2015, Myriad Genetics, Inc.
Advertisement
For the current quarter, Myriad expects revenue between $168 million and $170 million with adjusted earnings in the range of 25 cents to 27 cents a share, well under analysts’ forecasts of $192 million and 42 cents a share. Fiduciary Management Associates LLC purchased a new stake in shares of Myriad Genetics during the fourth quarter worth about $17,415,000.
